BB
BB Biotech Portfolio holdings
AUM
$3.98B
This Quarter Return
+17.86%
1 Year Return
+15.06%
3 Year Return
+120.36%
5 Year Return
+263.74%
10 Year Return
–
AUM
$3.06B
AUM Growth
+$3.06B
(+13%)
Cap. Flow
-$7.88M
Cap. Flow
% of AUM
-0.26%
Top 10 Holdings %
Top 10 Hldgs %
74.76%
Holding
30
New
1
Increased
13
Reduced
6
Closed
–
Top Buys
| 1 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$26.3M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$22M |
| 3 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
$6.99M |
| 4 |
RDUS
Radius Health, Inc.
RDUS
|
$6.96M |
| 5 |
MacroGenics
MGNX
|
$6.32M |
Top Sells
| 1 |
Incyte
INCY
|
$52.1M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
$23.1M |
| 3 |
CELG
Celgene Corp
CELG
|
$14.9M |
| 4 |
KITE
Kite Pharma, Inc.
KITE
|
$4.71M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
$3.55M |
Sector Composition
| 1 | Healthcare | 90.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Incyte
INCY
$16.5B
| $466M | 15.26% | 3,489,822 -390,000 | -10% | -$52.1M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $416M | 13.59% | 3,339,298 -120,000 | -3% | -$14.9M |
|
|
3
Ionis Pharmaceuticals
IONS
$6.79B
| $300M | 9.81% | 7,461,295 +548,123 | +8% | +$22M |
|
4
Gilead Sciences
GILD
$140B
| $188M | 6.16% | 2,774,596 | – | – |
|
|
RDUS
5
DELISTED
Radius Health, Inc.
RDUS
| $175M | 5.74% | 4,540,399 +180,000 | +4% | +$6.96M |
|
6
Agios Pharmaceuticals
AGIO
$2.19B
| $166M | 5.42% | 2,839,528 +30,000 | +1% | +$1.75M |
|
7
Vertex Pharmaceuticals
VRTX
$100B
| $159M | 5.21% | 1,455,445 +40,000 | +3% | +$4.37M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $149M | 4.88% | 1,229,428 | – | – |
|
9
Neurocrine Biosciences
NBIX
$13.8B
| $139M | 4.53% | 3,201,552 +50,000 | +2% | +$2.16M |
|
|
TSRO
10
DELISTED
TESARO, Inc.
TSRO
| $127M | 4.15% | 824,582 -150,000 | -15% | -$23.1M |
|
11
Halozyme
HALO
$8.56B
| $100M | 3.29% | 7,749,832 +150,000 | +2% | +$1.94M |
|
12
Regeneron Pharmaceuticals
REGN
$61.5B
| $94.9M | 3.11% | 245,000 | – | – |
|
|
SAGE
13
DELISTED
Sage Therapeutics
SAGE
| $69.1M | 2.26% | 972,439 -50,000 | -5% | -$3.55M |
|
14
Alnylam Pharmaceuticals
ALNY
$58.5B
| $63.6M | 2.08% | 1,241,338 +50,000 | +4% | +$2.56M |
|
|
KITE
15
DELISTED
Kite Pharma, Inc.
KITE
| $58.1M | 1.9% | 740,000 -60,000 | -8% | -$4.71M |
|
16
Esperion Therapeutics
ESPR
$448M
| $49.7M | 1.63% | 1,408,542 +100,000 | +8% | +$3.53M |
|
|
JUNO
17
DELISTED
Juno Therapeutics, Inc.
JUNO
| $48.5M | 1.59% | 2,185,000 +315,000 | +17% | +$6.99M |
|
|
18
MacroGenics
MGNX
$112M
| $42M | 1.38% | 2,260,000 +340,000 | +18% | +$6.32M |
|
|
MYOV
19
DELISTED
Myovant Sciences Ltd.
MYOV
| $38.8M | 1.27% | 3,302,835 +110,000 | +3% | +$1.29M |
|
|
ALDR
20
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $35.1M | 1.15% | 1,685,150 | – | – |
|
|
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $31.3M | 1.02% | 1,925,000 +350,000 | +22% | +$5.69M |
|
|
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $28.9M | 0.95% | 255,719 | – | – |
|
|
FPRX
23
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $26.3M | 0.86% | +727,500 | New | +$26.3M |
|
|
AVXS
24
DELISTED
AveXis, Inc. Common Stock
AVXS
| $25.3M | 0.83% | 332,800 -20,000 | -6% | -$1.52M |
|
25
Prothena Corp
PRTA
$441M
| $19.5M | 0.64% | 350,000 | – | – |
|